[1] Darvall KAL et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007;33(2):223–233. doi:10.1016/j.ejvs.2006.10.006
[2] Deutsche Adipositas-Gesellschaft (DAG) e.V.: Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie der Adipositas“, Version 2.0 (April 2014)
[3] Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69(6):546–554. doi:10.1212/01.wnl.0000267275.68538.8d
[4] Overvad TF et al. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke 2015;46(8):2168–2174. doi:10.1161/STROKEAHA.115.009371
[5] Fangel MV et al. Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study. Circ Arrhythm Electrophysiol 2019;12(5):e007030. doi:10.1161/CIRCEP.118.007030
[6] Hindricks G und Potpara T et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
[7] Lip GYH et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018;49(12):2933–2944. doi:10.1161/STROKEAHA.118.020232
[8] Deitelzweig S et al. Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J Clin Med 2020;9(6). doi:10.3390/jcm9061633
[9] Lip GYH et al. Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Mayo Clin Proc 2020;95(5):929–943. doi:10.1016/j.mayocp.2019.05.032.
[10] Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981–992. doi:10.1056/NEJMoa1107039
[11] Sandhu RK et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J 2016;37(38):2869–2878. doi:10.1093/eurheartj/ehw124
[12] Ezekowitz JA et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2015;1(2):86–94. doi:10.1093/ehjcvp/pvu024